Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma

NCT05547828 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

ESCC

Interventions

DRUG: Tislelizumab combined with chemoradiotherapy

Sponsor

The First Affiliated Hospital of Xinxiang Medical College

Collaborators

[object Object]